23andMe Is Sinking Fast. Can the Company Survive?

📆 01.10.2024 23:50:00
📰 WIREDScience

⏱ Reading Time:
25 sec. here
6 min. at publisher
📊 Quality Score:
News: 27%
Publisher: 55%

Science Nyheter

Business,Genetics,Whole-Genome Sequencing

The home DNA testing boom is over, and 23andMe is running out of options.

In August, the company shuttered its in-house drug discovery unit. And last month, all of the company’s board of directors resigned en masse over cofounder and CEO Anne Wojcicki’s “strategic direction,” which included a proposal to take the company private at 40 cents per share. Wojcicki had said she would consider third-party takeover offers but reversed course in a regulatory filing this week.

It partnered with Genentech back in 2015, and when that ended, it struck an exclusive deal with GlaxoSmithKline in 2018. The pharma company invested $300 million in 23andMe, but that agreement expired in 2023, with no big partners stepping in to fill Glaxo’s shoes. And while 23andMe recently shut down its drug discovery unit, it is continuing to advance the drug candidates it already has in clinical trials. Now, the company has turned to growing its telehealth business.

Skriv Kommentar

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

23andMe directors resign as the CEO of the genetic-testing company seeks to take it privateAll of 23andMe’s independent directors have resigned from its board in a rare move that marks the latest challenge for the genetic-testing company. The resignations follow drawn-out negotiations with 23andMe CEO and co-founder Anne Wojcicki who wants to take the company private.
Kilde: AP - 🏆 728. / 51 Les mer »